Overview

The Confirmatory Olmesartan Plaque Regression Study

Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Effect of olmesartan medoxomil (20-40 mg) on plaque regression in hypertensive patients with carotid atherosclerosis.
Phase:
Phase 4
Details
Lead Sponsor:
Daiichi Sankyo Europe, GmbH
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Treatments:
Atenolol
Olmesartan
Olmesartan Medoxomil